Maxim Grymonprez

650 total citations
33 papers, 406 citations indexed

About

Maxim Grymonprez is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maxim Grymonprez has authored 33 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Cardiology and Cardiovascular Medicine, 8 papers in Internal Medicine and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maxim Grymonprez's work include Atrial Fibrillation Management and Outcomes (26 papers), Cardiac Arrhythmias and Treatments (13 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Maxim Grymonprez is often cited by papers focused on Atrial Fibrillation Management and Outcomes (26 papers), Cardiac Arrhythmias and Treatments (13 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Maxim Grymonprez collaborates with scholars based in Belgium, Netherlands and Sweden. Maxim Grymonprez's co-authors include Lies Lahousse, Stéphane Steurbaut, Tine L. De Backer, Mirko Petrović, Koen Boussery, Els Mehuys, M. Arfan Ikram, Guy Brusselle, Bruno H. Stricker and Maryam Kavousi and has published in prestigious journals such as European Heart Journal, Thrombosis and Haemostasis and Age and Ageing.

In The Last Decade

Maxim Grymonprez

29 papers receiving 400 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maxim Grymonprez Belgium 12 345 96 80 57 44 33 406
Annya Stephens-Boal United Kingdom 3 451 1.3× 232 2.4× 95 1.2× 85 1.5× 14 0.3× 9 543
Lisa Naditch‐Brûlé France 13 668 1.9× 48 0.5× 67 0.8× 76 1.3× 13 0.3× 19 751
Martin E W Hemels Netherlands 12 435 1.3× 110 1.1× 48 0.6× 53 0.9× 16 0.4× 63 484
S. K. Rushton-Smith United Kingdom 10 670 1.9× 246 2.6× 133 1.7× 61 1.1× 13 0.3× 14 720
Jeroen Jaspers Focks Netherlands 7 193 0.6× 54 0.6× 33 0.4× 34 0.6× 17 0.4× 14 285
Gregory Lip United Kingdom 7 580 1.7× 172 1.8× 127 1.6× 43 0.8× 25 0.6× 12 649
Giovanni Nante Italy 10 303 0.9× 158 1.6× 64 0.8× 40 0.7× 9 0.2× 13 389
Annette Lemche Gulløv Denmark 5 528 1.5× 253 2.6× 133 1.7× 46 0.8× 34 0.8× 7 589
Hillary Mulder United States 9 241 0.7× 24 0.3× 54 0.7× 33 0.6× 40 0.9× 15 376
Steve Deitelzweig United States 10 456 1.3× 250 2.6× 70 0.9× 77 1.4× 7 0.2× 22 494

Countries citing papers authored by Maxim Grymonprez

Since Specialization
Citations

This map shows the geographic impact of Maxim Grymonprez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maxim Grymonprez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maxim Grymonprez more than expected).

Fields of papers citing papers by Maxim Grymonprez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maxim Grymonprez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maxim Grymonprez. The network helps show where Maxim Grymonprez may publish in the future.

Co-authorship network of co-authors of Maxim Grymonprez

This figure shows the co-authorship network connecting the top 25 collaborators of Maxim Grymonprez. A scholar is included among the top collaborators of Maxim Grymonprez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maxim Grymonprez. Maxim Grymonprez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grymonprez, Maxim, et al.. (2026). Guideline-directed medical therapy and mortality in heart failure patients hospitalized for COPD exacerbation. European Journal of Internal Medicine. 106830–106830.
2.
Grymonprez, Maxim, et al.. (2025). Predictors of mortality and hospitalised exacerbations in obstructive airway diseases. ERJ Open Research. 11(5). 1276–2024. 1 indexed citations
3.
Grymonprez, Maxim, et al.. (2025). Cardiovascular safety of biologic therapies in patients with severe asthma: a nationwide cohort study in Belgium. The Lancet Regional Health - Europe. 57. 101420–101420. 2 indexed citations
4.
Grymonprez, Maxim, et al.. (2024). Medication adherence to inhalation therapy and the risk of COPD exacerbations: a systematic review with meta-analysis. BMJ Open Respiratory Research. 11(1). e001964–e001964. 3 indexed citations
5.
Grymonprez, Maxim, Stéphane Steurbaut, Koen Boussery, et al.. (2023). Pharmacodynamic Drug-Drug Interactions and Bleeding Outcomes in Patients with Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants: a Nationwide Cohort Study. Cardiovascular Drugs and Therapy. 39(1). 133–143. 6 indexed citations
6.
Grymonprez, Maxim, Stéphane Steurbaut, Els Mehuys, et al.. (2023). Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death: A Nationwide Cohort Study. Cardiovascular Drugs and Therapy. 39(1). 107–117. 1 indexed citations
7.
Grymonprez, Maxim, Koen Boussery, Els Mehuys, et al.. (2023). Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. European Heart Journal - Cardiovascular Pharmacotherapy. 9(8). 722–730. 23 indexed citations
8.
Grymonprez, Maxim, et al.. (2023). Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. Frontiers in Pharmacology. 14. 1125576–1125576. 19 indexed citations
9.
Grymonprez, Maxim, Lu Dai, Amaia Calderón‐Larrañaga, et al.. (2023). Potentially inappropriate prescribing in multimorbid and polymedicated older adults with AF: A Systematic Review and Meta-Analysis. Drugs & Aging. 41(1). 13–30. 3 indexed citations
10.
11.
Grymonprez, Maxim, Tine L. De Backer, Els Mehuys, et al.. (2022). Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: A nationwide cohort study. British Journal of Clinical Pharmacology. 89(4). 1360–1373. 7 indexed citations
12.
Grymonprez, Maxim, et al.. (2022). Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study. European Heart Journal. 43(Supplement_2). 2 indexed citations
13.
14.
Grymonprez, Maxim, Stéphane Steurbaut, Els Mehuys, et al.. (2022). Adherence and persistence to oral anticoagulants in patients with atrial fibrillation: A Belgian nationwide cohort study. Frontiers in Cardiovascular Medicine. 9. 994085–994085. 21 indexed citations
15.
Wijnant, Sara, Daniël Bos, Guy Brusselle, et al.. (2021). Comparison of cerebral blood flow in subjects with and without chronic obstructive pulmonary disease from the population-based Rotterdam Study. BMJ Open. 11(12). e053671–e053671. 2 indexed citations
16.
17.
18.
Grymonprez, Maxim, Stéphane Steurbaut, Tine L. De Backer, Mirko Petrović, & Lies Lahousse. (2020). Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 11. 583311–583311. 60 indexed citations
19.
Grymonprez, Maxim, Stéphane Steurbaut, An De Sutter, & Lies Lahousse. (2020). Impact of a single non-sex-related stroke risk factor on atrial fibrillation and oral anticoagulant outcomes: a systematic review and meta-analysis. Open Heart. 7(2). e001465–e001465. 3 indexed citations
20.
Grymonprez, Maxim, Maryam Kavousi, Bruno H. Stricker, et al.. (2018). Chronic obstructive pulmonary disease and the development of atrial fibrillation. International Journal of Cardiology. 276. 118–124. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annya Stephens-Boal Breakdown of academic impact, for papers by Lisa Naditch‐Brûlé Breakdown of academic impact, for papers by Martin E W Hemels Breakdown of academic impact, for papers by S. K. Rushton-Smith Breakdown of academic impact, for papers by Jeroen Jaspers Focks Breakdown of academic impact, for papers by Gregory Lip Breakdown of academic impact, for papers by Giovanni Nante Breakdown of academic impact, for papers by Annette Lemche Gulløv Breakdown of academic impact, for papers by Hillary Mulder Breakdown of academic impact, for papers by Steve Deitelzweig
Rankless by CCL
2026